Accomplishments are evidenced by approved products and an advancing pipeline. Eight marketed and partnered products validate our technology and development approach.
Our collaborative approach to drug development is seen both internally and in successful partnerships. Partners include Novartis, Sandoz, Baxter and GSK.
Our formulation technologies and proprietary devices enable delivery directly to the lungs and underpin the company’s development pipeline.
Know-how and experience fuels innovation. Our experienced teams of scientists focus on developing innovative solutions in all areas of drug development.
Our drug development efforts are focused on airways – related diseases - a high unmet need and growing multi billion market.
Vectura is a respiratory product development Company. Enabled by our high-quality proprietary technologies, our experienced employees work hard to ensure we continue to be one of the leading names within our sector.
19 Aug 2014
Vectura Group plc - Interim Management Statement
30 Jun 2014
Vectura announces a further US collaboration agreement with a leading international pharmaceutical company for the VR506 asthma therapy
16 Oct 2014
Block Listing Return
09 Oct 2014
Approval in Portugal for AirFluSal Forspiro
Our innovative and broad clinical pipeline combines mid- and late-stage programmes with earlier-stage opportunities addressing large and fast-growing market sectors
View our product pipeline
Annual Report and Accounts for Year Ended 31 March 2014
View online report
VR315 US development milestone
Chippenham, UK - 24 June 2014: Vectura Group plc (LSE: VEC; "Vectura" or the "Company") announces that it has triggered a milestone of $1.5 million associated with the development of VR315 in the US.
Share price details
Interim Results for the six months ending 30 September 2014
Stay informed Register to our news alert and receive latest updates on news and events
For general enquiries, call us on +44 (0)1249 667700. For more specific enquiries, visit Contact us
Most computers will open PDF documents automatically, but you may need to download Adobe Reader.